AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbbVie (ABBV) shares rose 1.38% on May 29, 2025, with a trading volume of 9.12 billion, ranking 75th in the day's market activity.
AbbVie's
pipeline continues to advance with promising data from its investigational therapies. The company recently unveiled positive results for its novel c-Met-targeting antibody-drug conjugate (ADC), Temab-A, and the SEZ6-directed ADC. These therapies utilize AbbVie's proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to innovative cancer treatments.Additionally,
showcased new data across a range of difficult-to-treat solid tumors and blood cancers at the American Society of Clinical Oncology (ASCO) 2025 conference. This highlights the breadth and depth of AbbVie's oncology portfolio, which includes novel investigational ADCs such as telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer.Sarah Cannon Research Institute has announced a strategic alliance with AbbVie to advance novel cancer therapies. This partnership aims to accelerate the development of new treatments through community-based clinical trials, further strengthening AbbVie's position in the oncology field.
Hunt down the stocks with explosive trading volume.

Dec.22 2025

Dec.22 2025

Dec.22 2025

Dec.22 2025

Dec.22 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet